scispace - formally typeset
Open AccessJournal ArticleDOI

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine

TLDR
Wang et al. as discussed by the authors reported a case of Guillain-Barre syndrome (GBS) after receiving the first dose of Pfizer - COVID-19 vaccine.
Abstract
Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, in December 2019, Coronavirus - 19 (COVID-19) has become a global pandemic with multiple neurological complications. In December 2020, two vaccines have been approved in the United States for the prevention of COVID-19. We report a case of Guillain-Barre Syndrome (GBS) after receiving the first dose of Pfizer - COVID-19 vaccine.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine.

TL;DR: In this article, the authors observed seven cases of Guillain-Barre syndrome (GBS) that occurred within 2 weeks of the first dose of vaccination and all seven patients developed severe GBS.
Journal ArticleDOI

Spectrum of neurological complications following COVID-19 vaccination.

TL;DR: A wide spectrum of neurological complications is continuously being reported following COVID-19 vaccination, such as cerebral venous sinus thrombosis, acute transverse myelitis, acute disseminated encephalomyelitis and acute demyelinating polyneuropathy.
Journal ArticleDOI

Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.

TL;DR: In this paper, the authors presented an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1, presented to hospital with a rapidly progressive ascending muscle weakness and back pain in the absence of any other triggers.
Journal ArticleDOI

COVID-19 mRNA vaccination leading to CNS inflammation: a case series.

TL;DR: In this paper, clinical and MRI features of seven individuals who received the Moderna (n = 3) or Pfizer (n= 4) SARS-CoV-2 mRNA vaccines were reported.
Journal ArticleDOI

Case of Guillain-Barré syndrome following COVID-19 vaccine.

TL;DR: In this article, the authors describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over three days, and the diagnosis of Guillain-Barre syndrome (GBS) was confirmed by lumbar puncture and nerve conduction studies.
References
More filters
Journal ArticleDOI

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.

TL;DR: A new-type coronav virus, tentatively named by World Health Organization as the 2019-new coronavirus (2019-nCoV), had caused this outbreak in Wuhan city, Hubei Province, China, it was announced today.
Journal ArticleDOI

Looking beyond COVID-19 vaccine phase 3 trials.

TL;DR: In this paper, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required, including how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, equitable distribution of vaccines and the logistics of global vaccine delivery, all of which are a prelude to a massive vaccination campaign targeting people of all ages.
Journal ArticleDOI

COVID-19-associated Guillain-Barré syndrome: The early pandemic experience.

TL;DR: GBS‐associated COVID‐19 appears to be an uncommon condition with similar clinical and EDx patterns to GBS before the pandemic, and future studies should compare patients with COvid‐19–associated GBS to those with contemporaneous non–COVID‐ 19 GBS and determine whether the incidence of GBS is elevated in those with CO VID‐19.
Journal ArticleDOI

Vaccines and Guillain-Barré Syndrome

TL;DR: There is little evidence to support a causal association with most vaccines, but the benefit of vaccines in preventing disease and decreasing morbidity and mortality, particularly for influenza, needs to be weighed against the potential risk of GBS.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome.